Background: Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging
| INTRODUCTION
Basophils (BA) and mast cells (MC) are major effector cells of anaphylactic reactions in patients suffering from IgE-dependent allergies. [1] [2] [3] Both cell types produce a number of biologically active mediators, including histamine, lipid mediators, and cytokines, and both cell types express high-affinity receptors for immunoglobulin E (IgE). [1] [2] [3] [4] [5] [6] Once activated by IgE receptor (IgER) cross-linking or other stimuli, BA and MC liberate their proinflammatory substances, which leads to allergic inflammation and the clinical symptoms of anaphylaxis. [4] [5] [6] [7] [8] The ability of BA and MC to respond to IgE-dependent stimuli (allergens) is dependent on genetic background factors, various signal transduction molecules, and the presence of activating cytokines. [7] [8] [9] The type and severity of an IgE-dependent (anaphylactic) reaction depends on additional variables, including the source and configuration of the allergen, organ-specific factors, and the numbers of BA and MC involved in the reaction. [10] [11] [12] [13] [14] BA and MC may increase in number in various immunologic diseases, in certain types of (chronic) infectious diseases, and in distinct hematologic neoplasms. Likewise, in patients with systemic mastocytosis (SM), the numbers of MC increase substantially in various organs. 3, 12, 13 When these patients are suffering from a concomitant IgE-dependent allergy, anaphylactic reactions may be severe or even life-threatening. 12, 13 IgER-dependent activation of BA and MC is accompanied by an increase in certain cell surface antigens, including CD63 and CD203c, and by activation of numerous downstream signaling pathways and molecules, including LYN, SYK, RAS, MAP kinases, PI3
kinase (PI3K), mTOR, and protein kinase C. [4] [5] [6] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The Bruton's tyrosine kinase (BTK) has been identified as another important downstream target in IgER-cross-linked BA. [27] [28] [29] [30] [31] In particular, it has been described that IgER cross-linking in BA is followed by phosphorylation of SYK and that SYK, once activated, is capable of phosphorylating BTK. [27] [28] [29] [30] [31] In addition, it has been described that BTK inhibition is associated with reduced mediator release in human BA. 32 The aims of this study were to explore whether BTK can serve as a therapeutic target in BA and MC and whether the BTK blockers currently used in clinical trials are able to suppress allergen-induced (IgERdependent) activation and histamine release. In addition, we examined the effects of these drugs on growth of BA and MC. The results of our study show that BTK inhibition by ibrutinib is a potent approach to suppress allergen-induced histamine release and activation in human BA. 34 The percentage of BA ranged from 0.1% to 1.5% in dextran preparations, and from 0.3% to 2% in MNC. Cell viability was >90% as assessed by trypan blue exclusion test.
| MATERIAL AND METHODS

| Cell lines
The human MC line HMC-1 was kindly provided by Dr. J.H. Butterfield (Mayo Clinic, Rochester, MN, USA). Two subclones were used, HMC- 40 Apoptosis was measured in drug-exposed cells by combined AnnexinV/propidium iodide (PI) staining following a published protocol. 36, 40 For cell cycle studies, drug-exposed cells were resuspended in 500 lL permeabilization buffer. Then, 40 lL PI was added and cell cycle distribution was analyzed on a FACSCalibur as described previously. 
| Statistical analysis
To determine the level of significance in drug incubation experiments,
histamine release experiments and surface staining experiments in BA and human cell lines, the paired Student's t test was applied. In case of multiple comparisons, the Bonferroni correction was performed. A P value of <0.05 was considered to indicate statistical significance.
3 | RESULTS
| Effects of targeted drugs on IgER downstream signaling molecules
To study drug effects on BTK activation and to explore the specificity of these effects, we examined the phosphorylation status of various IgER downstream signaling molecules in drug-exposed and IgER-cross-linked BA as well as in untreated or drug-exposed cell lines (HMC-1.1, HMC-1.2, KU812). We found that dasatinib, ibrutinib, AVL-292, and CNX-774 counteract anti-IgE-induced expression of pBTK in BA ( Figure 1A ). In addition, the SYK inhibitor P505-15 was found to block expression of pBTK in BA ( Figure 1A ). These drugs were also found to block pBTK expression in unstimulated HMC-1.1, HMC-1.2, and KU812 cells ( Figure 1B) . In control experiments, P505-15 also decreased expression of pSYK in IgER-crosslinked BA (not shown). We also found that ibrutinib as well as the other BTK blockers applied suppress expression of pSYK, pAKT, pS6, and pSTAT5 in HMC-1 and KU812 cells (Fig. S1 ). Of all drugs applied, dasatinib was found to exert most potent effects on expression of pBTK and BTK downstream kinase targets, thereby confirming the broad target interaction profile of this drug. (Table S4 ) and between 0.003 and 0.023 lmol/L (0.01AE0.01 lmol/L) in allergic patients (Table S3 ). The inhibitory effects of ibrutinib
(1 lmol/L) were seen at all allergen concentrations applied (Figure 2C) . We also examined ex vivo BA obtained from a patient before and during treatment with ibrutinib, and found that ibrutinib therapy is followed by downregulation of IgE-dependent histamine release in BA ( Figure 2D ). These data show that ibrutinib is a potent inhibitor of IgE-dependent secretion of histamine in BA.
| Effects of other BTK-targeting drugs on
IgE-dependent histamine release
In a next step, we confirmed the value of BTK as a potential drug target by applying other BTK blockers. In these experiments, Table S4 (nonallergic individuals) and Table S5 (Der p 2-and Phl p 5-allergic donors). Dasatinib was also applied as positive control and found to block allergen-induced histamine release at higher concentrations ( Figure 3C ), confirming our previous results. 38 However, at lower concentrations, dasatinib even promotes histamine release. 38 Of all drugs tested, ibrutinib was found to be the most potent inhibitor of allergen-induced histamine release in human BA (Table S5 ). Figure 5D and Table 1 ).
| Effects of ibrutinib on
| Effects of CNX-774 on cell cycle distribution and apoptosis in human BA and MC lines
We also examined CNX-774-exposed HMC-1 and KU812 cells for alterations in cell cycle distribution and signs of apoptosis. In these experiments, CNX-774 was found to exhibit no effect on cell cycle progression in the three cell lines tested (Fig. S2A ). CNX-774
induced an increase in apoptotic cells as determined by staining for AnnexinV/PI and active caspase-3 in the three cell lines examined (Fig. S2B) . However, this effect of CNX-774 was only seen at relatively high concentrations. Dasatinib also induced apoptosis in all three cell lines examined (not shown), confirming previous studies. Recent data suggest that ibrutinib blocks IgE-dependent activation and histamine release in normal blood BA. 32 In the present study, we were able to confirm this effect of ibrutinib. In addition, our data show that ibrutinib is also a potent inhibitor of allergen- 43 An alternative explanation would be that some of these targets are activated by BTK in BA and that the ibrutinibinduced effects on these additional targets were (in part) mediated through BTK inhibition. It is generally appreciated that ibrutinib is not recognizing SYK. Correspondingly, ibrutinib did not block phosphorylation of SYK in BA in our study. By contrast, the SYK inhibitor P505-15 was found to block phosphorylation of SYK in BA and to suppress histamine release, confirming our previous results. 44 As BTK is downstream of SYK, we also examined the effects of P505-15 on BTK activation. Indeed, as expected, P505-15 was found to suppress BTK activation in BA. Whether P505-15 blocks histamine secretion through BTK disruption or also in a BTK-independent manner remains unknown. We also applied other BTK inhibitors in order to confirm the role of BTK in IgE-dependent activation and histamine secretion. All BTK blockers examined, including dasatinib, were found to suppress IgE-dependent histamine secretion in BA.
With regard to dasatinib, these results confirm our previous data. 38, 42 However, of all drugs tested, the most potent blocker of allergen-induced histamine secretion in BA appears to be ibrutinib.
Recent data suggest that ibrutinib inhibits IgE-dependent upregulation of CD63 and CD203c on normal BA. 32 In the current study, we confirmed this drug effect. In addition, we were able to show that ibrutinib blocks allergen-induced upregulation of CD63 and CD203c in BA obtained from patients allergic to Der p 2 and/or Phl p5, with comparable IC 50 values. In addition, we found that ibrutinib inhibits IgE-dependent upregulation of CD13 and CD164 on BA.
Unexpectedly, however, the other BTK inhibitors tested did not counteract upregulation of CD13, CD63, CD164, or CD203c on BA.
From these data, one could speculate that the effects of ibrutinib on IgE-dependent upregulation of these activation antigens were mediated by other (additional) drug targets in BA. Alternatively, the inhibitory effects of the other drugs on BTK activation were too weak to result in downregulation of these CD molecules. contributed patient material and parts of the study design; and P.V.
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